fashion -WSS

fashion

author：comprehensive 2025-09-01 15:18:03 - browse：696

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout LOUD podcast: possible new ALS drug, artificial wombs

Wikipedia

focus

WSS

FDA seeking to stop procedures at two unregulated stem cell clinics

What Congress can do to address the rural doctor shortage

Intarcia’s device

What Congress can do to address the rural doctor shortage

Biotech stock slump in 2023: awaiting the turnaround

FDA panel to weigh approval of NurOwn, controversial ALS drug

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Virginia high school admissions case could be legal follow

What Congress can do to address the rural doctor shortage

Hollywood unions extend contract negotiations for actors

How AI helped researchers track recovery from depression

Sports medicine is finally prioritizing gender equality

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

The cancer drug shortage isn’t new — and neither are the solutions

STAT Virtual Event: Putting AI to the Test

Peter Hotez and the public health issue of online harassment

Twill hunts for pharma partner to market its depression app

hotspot

Senators: Long

15 die by electrocution after transformer explodes in northern India

BridgeBio heart drug succeeds in pivotal study

BridgeBio heart drug succeeds in pivotal study

Johnson & Johnson sues to stop Medicare negotiation

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

focus

Wikipedia

focus

leisure time